The US president has signed an executive order aimed at facilitating the scientific study of psychedelic substances, some of which suggest a potential antidepressant effect, particularly for treating post-traumatic stress disorder (PTSD) in American veterans. The primary objective is to allow the FDA to expedite its review of these molecules in order to more quickly assess their efficacy and safety.
In the United States, these substances generally remain prohibited or strictly controlled because they are classified as addictive. This classification severely limits clinical research. The executive order therefore aims to remove certain legal obstacles to allow researchers, physicians, and clinicians to conduct more comprehensive studies and, if the results warrant it, to develop structured therapeutic protocols.
Among the substances mentioned is ibogaine, an alkaloid extracted from a shrub native to equatorial Africa. According to testimonials reported in the announcement, some patients have observed a significant reduction in their symptoms of depression and anxiety after one month of use. The text does, however, point out that this molecule carries risks, particularly cardiac risks, which necessitates in-depth research to assess its benefit-risk ratio.
 Frank Verain
|
20/04/2026 | 
Anglais
Arabic
Deutsch
Français
Español
Italien
Português
Russian